Analgesics in Switzerland

Analgesics in Switzerland

Analgesics will continue to register a positive performance in current value terms in Switzerland in 2024, driven largely by a notable rise in respiratory illnesses. This resurgence is partly due to reduced immunity as a result of lower viral transmission rates during the COVID-19 pandemic. With the increase in colds and flu, the use of analgesics for symptom relief, such as body aches and fever reduction, is growing. Adult acetaminophen is leading growth in category, driven by its widespread us...

Euromonitor International's Analgesics in Switzerland report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2019-2023, allowing you to identify the sectors driving growth. Forecasts to 2028 illustrate how the market is set to change.

Product coverage: Systemic Analgesics, Topical Analgesics/Anaesthetic.

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?
* Get a detailed picture of the Analgesics market;
* Pinpoint growth sectors and identify factors driving change;
* Understand the competitive environment, the market’s major players and leading brands;
* Use five-year forecasts to assess how the market is predicted to develop.